The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Gastric cancer: epidemiology, prevention, and therapy
Abstract
Gastric cancer (GC) is still the third leading cause of cancer death in both sexes worldwide. Helicobacter pylori infection is the most important risk factor for GC and, in spite of the consistent trend of a decreasing incidence, in 2015 approximately 4.4 billion individuals—more than half the world's population—were infected with H. pylori. The birth cohort pattern of decreased H. pylori infection reported in a systematic review contributes to explain the declining GC mortality in Japan. Current trends in estimated annual percentage change of GC incidence foreshadow expected reversals in both falling incidence and male predominance among US non‐Hispanic whites. Combining serum pepsinogen 1 and H. pylori serology was shown to be useful for GC risk stratification in a Finnish population. Gastritis staging by operative link on gastritis assessment was confirmed to be reliable in predicting GC risk in a large prospective study. In a randomized trial from South Korea, H. pylori eradication therapy significantly reduced the rates of metachronous GC in patients who received curative endoscopic resection for early GC. A study based on a territory‐wide health care database of the Hong Kong Hospital Authority showed that aspirin use is associated with a reduced GC risk. Another study based on the same database showed that proton pump inhibitors increase GC risk, but methodological biases have most likely acted as confounders. Confirmatory data on the role of endoscopic submucosal dissection in patients with early GC have been published. The phase III FLOT 4 trial has shown that the FLOT triplet regimen (docetaxel, oxaliplatin, leucovorin, and 5‐fluorouracil) improves the outcome of patients with GC and locoregional disease as compared to the ECF triplet (epirubicin, cisplatin, and 5‐fluorouracil). In the phase III ATTRACTION‐2 trial, nivolumab was shown to be an effective treatment option with a relative safe profile for heavily pretreated patients with advanced GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites
Anderson, W. F., Rabkin, C. S., Turner, N., Fraumeni, J. F., Rosenberg, P. S., & Camargo, M. C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx262 · Cited by 270
Cited by
Circular RNA: a novel biomarker and therapeutic target for human cancers
Lei, B., Tian, Z., Fan, W., & Ni, B. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.28047 · Cited by 313
Fu, D., Wang, C., Yu, L., & Yu, R. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00271-y · Cited by 283
Metadata
- Authors
- Venerito, M., Vasapolli, R., Rokkas, T., & Malfertheiner, P.
- Venue
- Helicobacter
- Publisher
- Wiley
- Published
- 2018-09
- Volume
- 23
- Issue
- S1
- Pages
- e12518-e12518
- ISSN
- 1083-4389 (ISSN-L)
- 1523-5378
- OpenAlex
- W2890230637
- Cited by
- 170
- References
- 1
- FWCI
- 25.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastric cancer: epidemiology, prevention, and therapy. https://app.cochat.ai/papers/10.1111/hel.12518
- The paper
- Venerito, M., Vasapolli, R., Rokkas, T., & Malfertheiner, P. (2018). Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. https://doi.org/10.1111/hel.12518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.